A peptide that stimulates receptors in neurons reduced the amount of toxic tau...
A peptide that stimulates receptors in neurons reduced the amount of toxic tau proteins present. Tau proteins are labeled yellow. Left image shows untreated neurons; right image shows neurons treated with the peptide.

Images from Natura Myeku

Battle for the brain

New Alzheimer's treatment approach targets tau

A new idea for treating Alzheimer’s disease could eradicate the toxic proteins most closely linked to cognitive decline in the places where they do the most damage, a study from researchers at Columbia University Vagelos College of Physicians and Surgeons suggests.

The study was published online in Science Translational Medicine.

Early in Alzheimer’s disease, toxic tau proteins accumulate inside the brain’s synapses, compromising the transmission of signals from one neuron to another. Cognitive decline in Alzheimer’s is closely linked to tau: the more tau that accrues, the faster cognition deteriorates. Eradicating toxic tau could improve cognition in Alzheimer’s patients, and in a previous study, the Columbia team discovered that tau levels can be reduced by enhancing the activity of proteasomes, cell structures that degrade old or unwanted proteins. “Enhancing proteasome activity improves cognition in mice that make a lot of mutant tau, but we don’t want to boost protein degradation throughout the cell where too much might cause unwanted effects,” says the study’s senior author Natura Myeku, PhD, assistant professor of pathology & cell biology at Columbia University Vagelos College of Physicians and Surgeons.

By targeting a certain family of receptors that are present mainly on the surface of synapses, our study raises the possibility of a whole new approach to remove toxic proteins in Alzheimer’s

Natura Myeku

The new study reveals a potential solution. The most toxic tau proteins, the researchers found, accumulate predominantly on one side of the synapse. And the activity of proteasomes on that side of the synapse can be amplified without affecting proteasomes in other parts of the brain.

Myeku’s team found that a peptide that stimulates PAC1 receptors, which are largely found on the same side of the synapse as tau, reduced toxic tau levels and improved cognitive performance in mice with early-stage tau accumulation. The peptide had little effect on the other side of the synapse. “Although the peptide is quickly degraded in the body and not a good candidate for therapy in humans,” Myeku says, “we are currently testing another drug, prucalopride, for the same purpose.” Prucalopride, which stimulates a receptor with similar action as PAC1, was recently approved by the FDA for the treatment of gastrointestinal disease. “By targeting a certain family of receptors that are present mainly on the surface of synapses, our study raises the possibility of a whole new approach to remove toxic proteins in Alzheimer’s and other neurodegenerative diseases, such as Parkinson’s and Huntington’s.” Myeku says.


Source: Columbia University

27.05.2021

Read all latest stories

Related articles

Photo

Intra-nasal administration

Microrobots for treating neurological diseases

The joint research team of Prof. Hongsoo Choi (DGIST) & Prof. Sung Won Kim (Seoul St. Mary’s Hospital), developed an hNTSC-based microrobot for minimally invasive delivery into the brain tissue…

Photo

Neurodegeneration

Scientists identify the cause of Alzheimer’s progression in the brain

For the first time, researchers have used human data to quantify the speed of different processes that lead to Alzheimer’s disease and found that it develops in a very different way than previously…

Photo

Brain stimulation

Infrared light helmet might aid dementia patients

Researchers at Durham University are working on a new infrared light therapy that might have the potential to help people with dementia. In the approach, people wear a specially adapted helmet which…

Related products

mediaire – mdbrain

Artificial Intelligence

mediaire – mdbrain

mediaire GmbH
Sarstedt – CSF false-bottom tube

CSF and Alzheimer’s Disease Diagnostics

Sarstedt – CSF false-bottom tube

SARSTEDT AG & CO. KG
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Mass Spectrometry

Shimadzu – CLAM-2030

Shimadzu Europa GmbH
Shimadzu – LCMS-8060NX (RUO)

Mass Spectrometry

Shimadzu – LCMS-8060NX (RUO)

Shimadzu Europa GmbH
Subscribe to Newsletter